Jeppe Øvlesen, Chairman of ResoTher Pharma, is pleased to announce that biotech veteran Kirsten Drejer, PhD joins the Board of Directors effective immediately. Dr. Drejer brings with her significant leadership and company building experience from her many years as co-founder and CEO of Symphogen A/S. Additionally, Dr. Drejer will leverage her considerable BoD experience from both large and small biotechs including Symphogen, Zealand Pharma, BioPorto, and Antaq Therapeutics in order to help advance the development of ResoTher Pharma.
Kirsten Drejer joins Board of Directors
|Published on: Apr 30, 2018||